A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Exclusion Criteria

• •For DLBCL and NHL:
• •\- Has lymphoplasmacytic lymphomas, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia (not associated with small lymphocytic lymphoma), Burkitt (-like) lymphoma, mature T cell and NK cell neoplasms, immunodeficiency associated lymphoproliferative neoplasms, or histiocytic and dendritic cell neoplasms.
• •For MM:
• •Has oligo-secretory myeloma, plasma cell leukemia, smoldering multiple myeloma, or monoclonal gammopathy of undetermined significance.
• •Has a history of primary amyloidosis, hyperviscosity or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
• •Has known prior or current central nervous system (CNS) involvement.
• •For Epstein Barr virus (EBV) positive DLBCL:
• •\- Associated with a solid organ transplant.
• •For all participants:
• •A WOCBP who has a positive urine pregnancy test within 72 hours before study intervention allocation.
• •Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.
• •Has a history of a second malignancy.
• •Any PMBCL participants that require the use of urgent cytoreductive therapy.
• •If the participant had major surgery, the participant must have recovered adequately from the procedure and/or any complications from the surgery before starting study intervention.
• •Has received prior radiotherapy within 2 weeks of start of study intervention.
• •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
• •Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.
• •Has a known severe hypersensitivity to MK-7684A, vibostolimab or pembrolizumab and/or any of its excipients.
• •Has a known history of Human Immunodeficiency Virus (HIV) infection.
• •Has an active autoimmune disease that has required systemic treatment in past 2 years.
• •Has an active infection requiring systemic therapy.
• •Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
• •Has present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks before enrollment.
• •Has dual active HBV infection (HBsAg (+) and /or detectable HBV DNA) and Hepatitis C (HCV) infection (anti-HCV Ab (+) and detectable HCV RNA) at study entry..
• •Has had an allogenic hematopoietic stem cell/solid organ transplantation within the last 5 years.